FDA Removes Decades-Old Black Box Warnings from Menopause Hormone Patches

The US Department of Health announced in late October 2026 the removal of broad black box warnings — the FDA's most serious cautionary label — from three estradiol transdermal patches prescribed for menopause symptoms, a change that was widely reported on 3 November. The original black box warnings were added in 2003 following the Women's Health Initiative study, which cited elevated risks of cardiovascular disease, breast cancer and probable dementia associated with hormone therapy. Critics argued for years that those findings were based on an older, higher-dose formulation given to older post-menopausal women and did not accurately reflect the risk profile of modern transdermal patches used in symptomatic, early-menopausal women. The FDA's action removes the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning on the three patches, though warnings about endometrial cancer remain in place for oestrogen-only products without a progestogen. Earlier in 2026, labelling changes had already been applied to six other hormone therapy products. Specialists welcomed the decision as overdue, saying the outdated warnings had caused widespread under-treatment of debilitating menopause symptoms and fuelled unnecessary fear. They stressed, however, that the removal of the black box does not mean the treatments are risk-free, and that individual women should discuss their personal and family health histories with their doctors before starting therapy.